Arbutus Biopharma

434 articles with Arbutus Biopharma

• Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

  3/16/2023

  Arbutus Biopharma Corporation today announced that the first subject has been dosed in the Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of AB-161.

• Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

  3/14/2023

  Arbutus Biopharma Corporation announced that preclinical data for AB-343, our novel oral SARS-CoV-2 Mpro inhibitor, has been presented in poster format at the 36th International Conference on Antiviral Research, in Lyon, France.

• Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update

  3/2/2023

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reported fourth quarter and year end 2022 financial results and provided a corporate update.

• Arbutus to Participate in Three Upcoming Investor Conferences

  2/6/2023

  Arbutus Biopharma Corporation today announced that the Arbutus management team will participate in and host one-on-one meetings at the following three upcoming investor conferences.

• Arbutus Announces Resignation of Board Member

  1/27/2023

  Arbutus Biopharma Corporation today announced that Tram Tran, MD has notified the Company of her intention to resign from the Company’s Board of Directors, effective February 26, 2023.

• Arbutus Announces 2023 Corporate Objectives and Provides Financial Update

  1/5/2023

  Arbutus Biopharma Corporation today announced its 2023 corporate objectives and provided a financial update.

• Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

  12/13/2022

  Arbutus Biopharma Corporation today announced preliminary data from the AB-729 lead-in portion of its Phase 2a clinical trial combining AB-729 with nucleos(t)ide analogue (NA) therapy and Peginterferon alfa-2a (IFN).

• Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/9/2022

  Arbutus Biopharma Corporation today reports its third quarter 2022 financial results and provides corporate updates.

• Arbutus to Present at Jefferies London Healthcare Conference

  11/8/2022

  Arbutus Biopharma Corporation today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 11:30 am GMT / 6:30 am EDT.

• Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update

  10/26/2022

  Arbutus Biopharma Corporation today announced that it has scheduled its third quarter 2022 financial results and corporate update for Wednesday, November 9, 2022.

• Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End

  9/30/2022

  Arbutus Biopharma Corporation today announced that Gaston Picchio, PhD, Chief Development Officer, will be leaving the Company for personal reasons.

• Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference

  9/22/2022

  Arbutus Biopharma Corporation today announced that the Company will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference taking place in New York on Tuesday, October 4, 2022 at 2:30 pm ET.

• Arbutus to Participate in September 2022 Investor Conferences

  9/6/2022

  Arbutus Biopharma Corporation announced that the Company will participate in the following upcoming investor conferences taking place in New York.

• Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729

  8/30/2022

  Arbutus Biopharma Corporation today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,427,823, which provides composition of matter patent protection for Arbutus’ AB-729 RNAi therapeutic product.

• Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/4/2022

  Arbutus Biopharma Corporation today reports its second quarter 2022 financial results and provides corporate updates.

• Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

  7/21/2022

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022.

• Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update

  6/25/2022

  Arbutus Biopharma Corporation announced the presentation of new clinical and pre-clinical data from its proprietary compounds at the European Association for the Study of the Liver International Liver Congress™.

• Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022

  6/8/2022

  Arbutus Biopharma Corporation announced that seven abstracts have been accepted for poster presentations at the European Association for the Study of the Liver International Liver Congress™ 2022 taking place June 22 - 26, 2022 in London, UK.

• Arbutus to Participate in June Investor Conferences

  6/2/2022

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York.

• 

  Clinical Hold on Antios' HBV Therapy Ends Deal with Assembly

  5/25/2022

  Antios Therapeutics received a clinical hold on its Hepatitis B virus (HBV) combinatorial therapy from the U.S. Food and Drug Administration on Wednesday.